Renalytix PLC (RNLX)

Form DEF 14A - Other definitive proxy statements

Form 8-K/A - Current report: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Commencement of trading on OTCQB in the United States

LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an...

Form 8-K - Current report

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX...

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX...

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]